Prosecution Insights
Last updated: November 04, 2026

Innovative Cellular Therapeutics Holdings Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Innovative Cellular Therapeutics Holdings Ltd. operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company has 1 pending office action currently active. This indicates a focused effort to protect a specific biological or pharmaceutical innovation through the patent office. The current level of activity suggests that the company is in a critical stage of securing rights for its core cellular therapy technology.

The prosecution is handled by a distinct examiner and 1 distinct art unit. This suggests that the company's current filings fall within a specialized technical category. ESTELLA M GUSTILO is the busiest examiner for the portfolio, currently managing the busiest examiner pending office action. This examiner is the only official currently reviewing the company's pending claims, which provides an opportunity for a consistent and focused technical dialogue.

For the legal team, the presence of the distinct art unit simplifies the procedural landscape. Because there is 1 pending office action, the prosecution strategy is entirely centered on the feedback from ESTELLA M GUSTILO. This allows for a concentrated response to any rejections within the Biotechnology & Pharmaceuticals sector, ensuring that the technical arguments are specifically tailored to the examiner's requirements and the standards of the assigned art unit.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
1
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GUSTILO, ESTELLA M 1 53.6% +34.5%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17295364 Modified Cell Expressing Therapeutic Agent and Uses thereof GUSTILO, ESTELLA M 34d

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17295364 Modified Cell Expressing Therapeutic Agent and Uses thereof GUSTILO, ESTELLA M 34d

Top Art Units

Art UnitApps
1646 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
17295364 Modified Cell Expressing Therapeutic Agent and Uses thereof GUSTILO, ESTELLA M 1646 §103§112Other Non-Final OA 34d Pending May 19, 2021

Managing Innovative Cellular Therapeutics Holdings Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Innovative Cellular Therapeutics Holdings Ltd. have?

Innovative Cellular Therapeutics Holdings Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Innovative Cellular Therapeutics Holdings Ltd. applications?

Estella M Gustilo has the most, with 1 of Innovative Cellular Therapeutics Holdings Ltd.'s pending office actions.

What technology area are Innovative Cellular Therapeutics Holdings Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month